fbpx

Nyheder

Lundbeckfonden Ventures nyheder

Type C Meeting confirmed that FDA does not believe additional clinical safety, efficacy, or pharmacology studies will be required to support NDA resubmission and review FDA confirmed that the resubmission would be under the current NDA Company accelerates timeline and now expects resubmission of FUROSCIX NDA with the FDA by mid-year 2020 BURLINGTON, Mass., July...
Cambridge, UK and Indianapolis, US – 12 July 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) welcomes an editorial published in the leading peer-reviewed journal Anesthesia & Analgesia, accompanying the print publication of results from its positive Phase 3 clinical trial of BARHEMSYS® (intravenous amisulpride) as treatment of post-operative nausea & vomiting...
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 8 July 2019: Acacia Pharma Group plc (“Acacia Pharma” or “the Company”), a pharmaceutical company developing and commercialising hospital products for US and international markets, announces receipt of the official...
– Proceeds to enable progression of orphan designated lead candidate SNF472 into pivotal phase 3 trial for treatment of calciphylaxis – Round led by Spanish investor Caixa Capital Risc – Deal supported by new investors Columbus Venture Partners and Alta Life Sciences in addition to international consortium of existing shareholders Palma, Spain and San Diego,...
DURHAM, North Carolina and NESS ZIONA, Israel, June 18, 2019 /PRNewswire/ — Atox Bio, a late stage clinical company developing immunotherapies for critically ill patients, today announced the Biomedical Advanced Research and Development Authority (BARDA) has exercised the next option on a performance-based contract with for the development of Reltecimod in patients with Necrotizing Soft Tissue Infections (NSTI).  Reltecimod is...
San Diego – May 20, 2019 – Reneo Pharmaceuticals, a clinical stage pharmaceutical company, today announced that it has completed a $50 million Series A financing to develop therapies for diseases associated with deficits in cellular metabolism and energy production. The A round was led by New Enterprise Associates. Other participants in the round include Lundbeckfonden...
Today, on 14 May 2019, an annual shareholders’ meeting was held in BONESUPPORT HOLDING AB. A summary of the resolutions adopted follows below. All resolutions were adopted with the required majority. Resolution on adoption of accounts and allocation of the company’s result The annual shareholders’ meeting resolved to adopt the profit and loss statement and...
New post-hoc subset analysis from positive Phase 3 trial selected as part of the Excellence and Innovation Awards to be presented at SAMBA 2019 Cambridge, UK and Indianapolis, US – 10 May 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) announces that an abstract reporting additional data and analyses from its positive...
Cambridge, UK and Indianapolis, US – 7 May 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients, announces that its annual general meeting of shareholders (“AGM”) will be held at 11.00 am...
1 2 3 58

Lundbeckfonden Ventures

Nyheder

scPharmaceuticals Inc. Provides Regulatory Update on FUROSCIX®
16. juli 2019
Acacia Pharma Group PLC – Editorial on Positive Data for BARHEMSYS® Treatment of Post-Operative Nausea & Vomiting (PONV) Published in Anesthesia & Analgesia
12. juli 2019
Acacia Pharma Group PLC – Acacia Pharma Plans to Resubmit the BARHEMSYS® NDA in Q3 2019
8. juli 2019